Clinical trials: Lymphoma
CD19+ Diffuse Large B-cell Lymphomas, Follicular Lymphomas
Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas
Single center, phase I/II trial of pembrolizumab after CTL019 for CD19+ lymphomas. Patients will have CD19+ diffuse large B-cell, follicular, or mantle cell lymphomas relapsed/refractory after CTL019.
- Conditions
- CD19+ Diffuse Large B-cell Lymphomas, Follicular Lymphomas, Mantle Cell Lymphomas
- Trial name
- NCT02650999
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Richter's Transformation
PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)
This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It is a multi-center, single-arm, 2-stage, open-label phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety…
- Trial name
- NCT02378038
- Testing
- PNT2258
- Where
- 9 sites in United States
- Volunteers
- 5 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Recurrent Ependymoma, Recurrent Ewing Sarcoma
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well ivosidenib works in treating patients with solid tumors, including central nervous system tumors, lymphomas and histiocytic disorders that have not responded to (refractory) or…
- Conditions
- Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis
- Trial name
- NCT04195555
- Testing
- Ivosidenib
- Where
- 174 sites in United States, Australia and 1 more
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma
MabionCD20 Compared to MabThera in Lymphoma Patients
The aim of the study is to demonstrate the high level of biosimilarity between MabionCD20 (MABION SA) and the reference product: MabThera (rituximab by Hoffman-La Roche) in patients with CD20-positive diffuse large B-cell…
- Trial name
- MADILYM (NCT02617485)
- Testing
- Rituximab, Doxorubicin, Vincristine
- Where
- 35 sites in Bosnia and Herzegovina, Croatia and 5 more
- Volunteers
- 143 people
- Sponsor
- Mabion SA
Non-Hodgkin's Lymphoma
A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.
This study will measure the effectiveness and any side effects of LY317615 in participants with diffuse large B-cell lymphoma (DLBCL: a sub-type of Non-Hodgkins Lymphoma).
- Trial name
- NCT00042666
- Testing
- LY317615
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- Eli Lilly and Company
Prolapsed Lumbar Disc, Prolapsed Cervical Disc
Patient Registry to Observe Outcomes Following Implantation of the VariLift Interbody Fusion Device
The registry has been designed as a prospective, observational program for patients undergoing lumbar or cervical fusion using VariLift device with the ultimate goal to aid in the development of strategic treatment pathways and…
- Conditions
- Prolapsed Lumbar Disc, Prolapsed Cervical Disc, Intervertebral Disc Degeneration, Spondylolisthesis, Grade 1
- Trial name
- NCT01944345
- Where
- 3 sites in United States
- Volunteers
- 69 people
- Sponsor
- Wenzel Spine
Leukemia, Lymphoma
Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases
Donor: This clinical study will evaluate the feasibility of a purified CD34 peripheral blood progenitor cell (PBPC) transplants in patients with hematological malignancies.
- Trial name
- NCT00038857
- Testing
- Megadose of CD34 Selected Progenitor Cells, Melphalan, Thiotepa
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Lymphocytic, Chronic, B-Cell
A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Safety, pharmacokinetics, and preliminary efficacy of CC-122 alone and in combination with ibrutinib and obinuzutumab. CC-122 has multiple activities, including immune modulation of several immune cell subsets and…
- Trial name
- ENHANCE (NCT02406742)
- Testing
- CC-122, Ibrutinib, Obinutuzumab
- Where
- 24 sites in United States, Austria and 3 more
- Volunteers
- 47 people
- Sponsor
- Celgene
Leukemia, Lymphoma
Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RATIONALE: Drugs used in chemotherapy, such as pentostatin and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00816595
- Testing
- bevacizumab, pegfilgrastim, rituximab
- Where
- 2 sites in United States
- Volunteers
- 68 people
- Sponsor
- Mayo Clinic
Leukemia
Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation
The purpose of this study is to find out if getting a blood stem cell transplant with donor stem cells given over several days is better than getting a blood stem cell transplant with donor stem cells given over 1 day.
- Trial name
- NCT01596257
- Testing
- allogeneic hematopoietic stem cell transplantation, CliniMACS
- Where
- United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Lymphoid Leukemia, Acute Myeloid Leukemia
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
This is an open-label, multicenter, phase 2 clinical trial to evaluate the antitumor activity of brentuximab vedotin as a single agent in patients with CD30-positive nonlymphomatous malignancies.
- Conditions
- Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Anemia, Refractory, With Excess of Blasts, Solid Tumors
- Trial name
- NCT01461538
- Testing
- brentuximab vedotin
- Where
- 29 sites in United States
- Volunteers
- 84 people
- Sponsor
- Seagen Inc.
Diffuse Large B-cell Lymphoma
Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma
This study will evaluate whether a reduction in the radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late toxicity.
- Trial name
- DLBCL (NCT01186978)
- Testing
- Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- Duke University
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This is an open-label, single arm, and registered study of ATG-010 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
- Trial name
- SEARCH (NCT03992339)
- Testing
- ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle
- Where
- 18 sites in China
- Volunteers
- 60 people
- Sponsor
- Antengene Corporation
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)
This phase II MATCH treatment trial identifies the effects of trametinib in patients whose cancer has genetic changes called GNAQ or GNA11 mutations.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439357
- Testing
- Trametinib Dimethyl Sulfoxide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients
The purpose of the study is to investigate whether the combination of rituximab and high dose methylprednisolone can be given together, can reduce the amount of cancer cells that are present prior to starting venetoclax, and…
- Trial name
- NCT04981912
- Testing
- HDMP + rituximab as a means of debulking prior to initiating venetoclax.
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of California, San Diego
Lymphoma
Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma
The goal of this clinical research study is to learn if the combination of the immunotherapy drugs, CT-011 and rituximab, can help control follicular lymphoma. The safety of this drug combination will also be studied.
- Trial name
- NCT00904722
- Testing
- CT-011, Rituximab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)
The primary objective for the phase I part of the study is to investigate the safety and tolerability of escalating intravenous (IV) doses of obinutuzumab given as monotherapy in participants with CD20+ (tumor-infiltrating…
- Trial name
- NCT00517530
- Testing
- Obinutuzumab
- Where
- 16 sites in France, Germany
- Volunteers
- 134 people
- Sponsor
- Hoffmann-La Roche
Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma
Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH
FIL_Dara-GDP is a phase II, open label, multicenter clinical trial. The sponsor of this clinical trial is Fondazione Italiana Linfomi (FIL).
- Trial name
- NCT04251065
- Testing
- Daratumumab
- Where
- 7 sites in Italy
- Volunteers
- 8 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Leukemia, Lymphoma
Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00602836
- Testing
- Rituximab, Cyclophosphamide, Lenalidomide
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Mayo Clinic
Diffuse Large B-Cell Lymphoma
Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.
Multicentric randomized phase III study comparing high doses of chemotherapy with Rituximab followed by auto-transplant HPC versus CHOP plus Rituximab as first line therapy in high risk patients with DLBCL Non-Hodgkin's lymphomas.
- Trial name
- NCT00355199
- Testing
- Rituximab-HDS, Rituximab-CHOP
- Where
- 16 sites in Italy
- Volunteers
- 246 people
- Sponsor
- Gruppo Italiano Terapie Innovative nei Linfomi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.